Lonza adds X-ray powder diffraction to micronisation portfolio in Monteggio (CH)
Lonza expands solid-state characterisation services for polymorph and solid-state properties of APIs with the addition of X-ray powder diffraction to its portfolio.
Pharmaceutical and biotechnology manufacturing company Lonza has introduced X-ray powder diffraction (XRPD) into the portfolio of services offered by its Monteggio site, expanding its range of services to include additional information about polymorph and solid-state properties of active pharmaceutical ingredients (APIs).
Micronisation, the process of reducing the average diameter of a solid material’s particles, is a common technique used in the production of APIs and chemicals to increase their efficacy as particles with reduced diameters have higher dissolution rates. However, micronisation is an energetic process and may result in amorphous generation or polymorphic changes. Such changes can compromise the quality and stability of a product as it changes the physicochemical properties. Appropriate identification and characterisation of a materials solid state is crucial when minimizing stability-related challenges. XRPD offers a non-destructive method for the characterisation of crystalline materials.
The addition of XRPD to Lonza’s Monteggio (CH) site will enhance their comprehensive analytical capabilities with the generation of critical data for drug discovery development, and manufacturing. Associate Director, New Product Introduction and MSAT, Salvator Mercuri at Lonza Monteggio commented: “The implementation of XRPD provides additional analytical information, highlighting differences in the solid state of materials before and after micronisation and determining whether additional processing is needed. The XRPD improves our ability to detect solid state changes induced by the micronisation process early in development and allows the problem to be properly addressed before the process is defined. This will ensure that our processes continue to obtain stable products suitable for further processing and formulation.”
Dirk Knapp, Site Head at Lonza Monteggio, stated: “We continue to focus on improving our analytical toolbox to offer a full picture of the quality and stability of crystalline products. The expansion of our analytical capabilities in Monteggio creates a comprehensive offering that brings a multidisciplinary approach to API development and manufacturing.”
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance